2019
DOI: 10.1158/0008-5472.can-19-0040
|View full text |Cite
|
Sign up to set email alerts
|

HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy

Abstract: Increased HDAC8 activity deacetylates c-JUN, leading to increased EGFR signaling and BRAF inhibitor resistance Low HDAC8 activity RTK c-Jun High HDAC8 activity BRAFi c-Jun Ras RAF ERK Cell death Survival and invasion BRAFi Ras RAF ERK RTK (EGFR) ac ac ac TRE ac ac TRE p TR HDAC8 Melanoma cells have the ability to switch to a dedifferentiated, invasive phenotype in response to multiple stimuli. Here, we show that exposure of melanomas to multiple stresses including BRAF-MEK inhibitor therapy, hypoxia, and UV ir… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
59
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
5
3
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 62 publications
(63 citation statements)
references
References 48 publications
4
59
0
Order By: Relevance
“…One important clinical implication of this study is that the existence of the stress program can have consequences for the intrinsic responsiveness to therapy. In melanoma, for example, HDCA8 has been shown to mediate drug resistance under multiple stress conditions such as BRAF-MEK treatment, hypoxia, UV and radiation through regulation of MAPK, decrease in jun acetylation and enrichment of AP-1 signaling (Emmons et al, 2019) . HSF1 has been demonstrated to be essential for chemotherapeutic agent-induced cytoprotective autophagy by directly binding to ATG7 in breast cancer (Desai et al, 2013) and active in colon and lung tumors as well (Mendillo et al, 2012) .…”
Section: Discussionmentioning
confidence: 99%
“…One important clinical implication of this study is that the existence of the stress program can have consequences for the intrinsic responsiveness to therapy. In melanoma, for example, HDCA8 has been shown to mediate drug resistance under multiple stress conditions such as BRAF-MEK treatment, hypoxia, UV and radiation through regulation of MAPK, decrease in jun acetylation and enrichment of AP-1 signaling (Emmons et al, 2019) . HSF1 has been demonstrated to be essential for chemotherapeutic agent-induced cytoprotective autophagy by directly binding to ATG7 in breast cancer (Desai et al, 2013) and active in colon and lung tumors as well (Mendillo et al, 2012) .…”
Section: Discussionmentioning
confidence: 99%
“…The list of compounds based on their nominal targets included two HDAC inhibitors (Fimepinostat and Givinostat), two BET bromodomain inhibitors (Birabresib and I-BET762), two KDM1A inhibitors (SP2509 and ORY-1001), a pan Jmj-KDM inhibitor (JIB-04), a KDM5 inhibitor (CPI-455), two Tankyrase inhibitors (AZ6102 and NVP-TNKS656), and two CDK4/6 inhibitors (Palbociclib and Abemaciclib). These compounds were selected from two broad classes of anti-cancer drugs, referred to as epigenetic-modifying compounds and cell cycle inhibitors, which have been proposed to be used in combination with standard of care BRAF and MEK inhibitors to overcome drug-adapted subpopulations of cells in BRAF-mutant melanomas [10,21,[41][42][43][44][45][46][47][48][49].…”
Section: Probabilistic Phenotype Metrics Uncover Target-specific Diffmentioning
confidence: 99%
“…The high heterogeneity of the tumor cells and their plasticity lead to the possibility that the same drug might induce the switch to slow-cycling resistant phenotype associated to high melanocyte inducing transcription factor levels and to a mesenchymal-like phenotype [42][43][44][45][46] . Early adaptation involving transcriptome reprogramming seems to be particularly relevant even at long time scale, allowing the tumor to survive until a genetic mutation and permanent resistance mechanism is acquired [43,47] . Interestingly, melanoma cells can display profound transcriptional variability at the level of single cell that can involve the transcription of a number of resistance markers at high level in a very small percentage of cells [48] .…”
Section: Genetic and Epigenetic Mechanisms Of Resistancementioning
confidence: 99%